Sodium Chromate Cr 51 Injection
Chromic acid (H251CrO4), disodium salt.
Disodium chromate (Na251CrO4)
[7775-11-3].» Sodium Chromate Cr 51 Injection is a sterile solution of radioactive chromium (51Cr) processed in the form of sodium chromate in Water for Injection. For those uses where an isotonic solution is required, Sodium Chloride may be added in appropriate amounts as provided under Injections 
1
. Chromium 51 is produced by the neutron bombardment of enriched chromium 50.
1. Chromium 51 is produced by the neutron bombardment of enriched chromium 50.Sodium Chromate Cr 51 Injection contains not less than 90.0 percent and not more than 110.0 percent of the labeled amount of 51Cr as sodium chromate expressed in megabecquerels (millicuries) per mL at the time indicated in the labeling. The sodium chromate content is not less than 90.0 percent and not more than 110.0 percent of the labeled amount. The specific activity is not less than 370 megabecquerels (10 millicuries) per mg of sodium chromate at the end of the expiry period. Other chemical forms of radioactivity do not exceed 10.0 percent of the total radioactivity.
Packaging and storage—
Preserve in single-dose or in multiple-dose containers.
Labeling—
Label it to include the following, in addition to the information specified for Labeling under Injections 1: the time and date of calibration; the amount of sodium chromate expressed in µg per mL; the amount of 51Cr as sodium chromate expressed as total megabecquerels (millicuries) and as megabecquerels (millicuries) per mL at the time of calibration; a statement to indicate whether the contents are intended for diagnostic or therapeutic use; the expiration date; and the statement “Caution—Radioactive Material.” The labeling indicates that in making dosage calculations, correction is to be made for radioactive decay and the quantity of chromium, and also indicates that the radioactive half-life of 51Cr is 27.8 days.
1: the time and date of calibration; the amount of sodium chromate expressed in µg per mL; the amount of 51Cr as sodium chromate expressed as total megabecquerels (millicuries) and as megabecquerels (millicuries) per mL at the time of calibration; a statement to indicate whether the contents are intended for diagnostic or therapeutic use; the expiration date; and the statement “Caution—Radioactive Material.” The labeling indicates that in making dosage calculations, correction is to be made for radioactive decay and the quantity of chromium, and also indicates that the radioactive half-life of 51Cr is 27.8 days.
USP Reference standards 11—
USP Endotoxin RS.
11—
USP Endotoxin RS.
Radionuclide identification (see Radioactivity 821)—
Its gamma-ray spectrum is identical to that of a specimen of 51Cr of known purity that exhibits a photopeak having an energy of 0.320 MeV.
821)—
Its gamma-ray spectrum is identical to that of a specimen of 51Cr of known purity that exhibits a photopeak having an energy of 0.320 MeV.
Bacterial endotoxins 85—
It contains not more than 175/V USP Endotoxin Unit per mL of the Injection, when compared with the USP Endotoxin RS, in which V is the maximum recommended total dose, in mL, at the expiration date or time.
85—
It contains not more than 175/V USP Endotoxin Unit per mL of the Injection, when compared with the USP Endotoxin RS, in which V is the maximum recommended total dose, in mL, at the expiration date or time.
pH 791:
between 7.5 and 8.5.
791:
between 7.5 and 8.5.
Radiochemical purity—
Place a volume of Injection, appropriately diluted so that it provides a count rate of about 20,000 counts per minute, about 25 mm from one end of a 25- × 300-mm strip of chromatographic paper (see Chromatography 621), and immediately develop with a mixture of 5 parts of water, 2 parts of dilute alcohol (9.5 in 10), and 1 part of ammonium hydroxide. Air-dry the chromatogram, and determine the radioactivity distribution by scanning the chromatogram with a suitable collimated radiation detector. The radioactivity of the chromate band is not less than 90.0% of the total radioactivity. The RF value for the chromate band falls within ±10% of the value found for a known sodium chromate specimen when determined under identical conditions.
621), and immediately develop with a mixture of 5 parts of water, 2 parts of dilute alcohol (9.5 in 10), and 1 part of ammonium hydroxide. Air-dry the chromatogram, and determine the radioactivity distribution by scanning the chromatogram with a suitable collimated radiation detector. The radioactivity of the chromate band is not less than 90.0% of the total radioactivity. The RF value for the chromate band falls within ±10% of the value found for a known sodium chromate specimen when determined under identical conditions.
Other requirements—
It meets the requirements under Injections 1, except that it is not subject to the recommendation on Volume in Container.
1, except that it is not subject to the recommendation on Volume in Container.
Assay for sodium chromate—
Standard stock preparation—
Dissolve 3.735 g of potassium chromate in 1000 mL of water to obtain a solution having a known concentration of 1.0 mg per mL of chromium.
Standard preparation—
Pipet 0.25, 0.50, 0.75, 0.100, 0.125, and 0.150 mL of the Standard stock preparation, accurately measured, into separate 100-mL volumetric flasks. To each flask add 0.42 mL of 0.1 N sodium bicarbonate, and dilute with water to volume to obtain solutions having final concentrations of 0.25, 0.50, 0.75, 1.00, 1.25, and 1.50 µg of chromium per mL.
Assay preparation—
Use the Injection.
Blank preparation—
Transfer 0.42 mL of 0.1 N sodium bicarbonate to a 100-mL volumetric flask, and dilute with water to volume.
Procedure—
Concomitantly determine the absorbances of the Assay preparation, the Standard preparations, and the Blank preparation at the chromium emission line at 357.7 nm with a suitable atomic absorption spectrophotometer (see Spectrophotometry and Light-Scattering 851) equipped with a chromium hollow-cathode lamp and an air–acetylene (fuel-rich) flame using water to set the instrument to zero. Plot the absorbances of the Standard preparations and the Blank preparation versus concentration, in µg per mL, of chromium, and perform a regression analysis. A suitable standard curve will have an intercept between –0.002 and +0.002, and a regression coefficient of not less than 0.99. Using the standard curve so obtained, determine the concentration, C, in µg per mL, of chromium in the Injection taken. Calculate the quantity of sodium chromate, in µg per mL, by the formula:
851) equipped with a chromium hollow-cathode lamp and an air–acetylene (fuel-rich) flame using water to set the instrument to zero. Plot the absorbances of the Standard preparations and the Blank preparation versus concentration, in µg per mL, of chromium, and perform a regression analysis. A suitable standard curve will have an intercept between –0.002 and +0.002, and a regression coefficient of not less than 0.99. Using the standard curve so obtained, determine the concentration, C, in µg per mL, of chromium in the Injection taken. Calculate the quantity of sodium chromate, in µg per mL, by the formula:
3.115C
in which 3.115 is the conversion factor.
Assay for radioactivity—
Using a suitable counting assembly (see Selection of a Counting Assembly under Radioactivity 821), determine the radioactivity, in MBq (µCi) per mL, of Injection by use of a calibrated system as directed under Radioactivity 821.
821), determine the radioactivity, in MBq (µCi) per mL, of Injection by use of a calibrated system as directed under Radioactivity 821.
Auxiliary Information—
Please check for your question in the FAQs before contacting USP.
| Topic/Question | Contact | Expert Committee |
| Monograph | Ian DeVeau, Ph.D.
Director, Veterinary Drugs and Radiopharmaceuticals 1-301-816-8178 |
(RMI05) Radiopharmaceuticals and Medical Imaging Agents 05 |
| Reference Standards | Lili Wang, Technical Services Scientist 1-301-816-8129 RSTech@usp.org |
|
| 85 |
Radhakrishna S Tirumalai, Ph.D.
Senior Scientist 1-301-816-8339 |
(MSA05) Microbiology and Sterility Assurance |
USP32–NF27 Page 1927
Pharmacopeial Forum: Volume No. 27(3) Page 2526